Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2012 | 1 |
2022 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
Vaccine. 2022 Jul 29;40(31):4190-4198. doi: 10.1016/j.vaccine.2022.05.079. Epub 2022 Jun 9.
Vaccine. 2022.
PMID: 35690500
Free article.
Clinical Trial.
Participants received a single intramuscular injection of ASP3772 (1-, 2-, or 5-g dose per polysaccharide) or PCV13. A separate, nonrandomized group of PCV13-vaccinated participants (65-85 years) received PPSV23 (23-valent polysaccharide vaccine). ...Immunogenicity was mea …
Participants received a single intramuscular injection of ASP3772 (1-, 2-, or 5-g dose per polysaccharide) or PCV13. A separate, nonr …
The Eighth Liquid Matter Conference.
Dellago C, Kahl G, Likos CN.
Dellago C, et al.
J Phys Condens Matter. 2012 Jul 18;24(28):280301. doi: 10.1088/0953-8984/24/28/280301. Epub 2012 Jun 27.
J Phys Condens Matter. 2012.
PMID: 22740596
The Eighth Liquid Matter Conference contents The Eighth Liquid Matter ConferenceChristoph Dellago, Gerhard Kahl and Christos N Likos Comparing light-induced colloidal quasicrystals with different rotational symmetriesMichael Schmiedeberg and Holger Stark Hydrogen bond network rel …
The Eighth Liquid Matter Conference contents The Eighth Liquid Matter ConferenceChristoph Dellago, Gerhard Kahl and Christos N Likos Compari …
Item in Clipboard
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial.
Borys D, Rupp R, Smulders R, Chichili GR, Kovanda LL, Santos V, Malinoski F, Siber G, Malley R, Sebastian S.
Borys D, et al.
Vaccine. 2024 Apr 11;42(10):2560-2571. doi: 10.1016/j.vaccine.2024.02.001. Epub 2024 Feb 14.
Vaccine. 2024.
PMID: 38360475
Free article.
Clinical Trial.
Reactogenicity (within 7 days), treatment-emergent adverse events (TEAEs, within 180 days), serious/medically attended adverse events (SAEs/MAAEs, within 180 days), and immunogenicity (serotype-specific anti-capsular polysaccharide immunoglobulin G [IgG] and opsonophagocyt …
Reactogenicity (within 7 days), treatment-emergent adverse events (TEAEs, within 180 days), serious/medically attended adverse events (SAEs/ …
Item in Clipboard
Cite
Cite